SPYRE THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
SPYRE THERAPEUTICS, INC. (SYRE) reported Payments to Acquire Debt Securities, Available-for-sale of $528.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $447.34M, a 1182.96% increase year-over-year.
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $81.17M, a 13.61% increase year-over-year.
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $341.71M, a 46.60% increase year-over-year.
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $74.19M, a 111.66% increase year-over-year.
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $522.21M, a 12.86% decline from fiscal 2024.
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $599.25M, a 259.26% increase from fiscal 2023.
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $166.80M, a 322.29% increase from fiscal 2022.
- SPYRE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $39.50M, a 70.32% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $447.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $528.51M 10-Q · filed 2026-08-04 | $870.22M derived: sum of 3 quarters · filed 2026-08-04 | $944.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $81.17M 10-Q · filed 2026-05-05 | $422.88M derived: sum of 2 quarters · filed 2026-05-05 | $497.07M derived: sum of 3 quarters · filed 2026-05-05 | $531.94M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $341.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $415.90M derived: sum of 2 quarters · filed 2026-02-19 | $450.77M derived: sum of 3 quarters · filed 2026-08-04 | $522.21M 10-K · filed 2026-02-19 |
| 2025-09-30 | $74.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $109.06M derived: sum of 2 quarters · filed 2026-08-04 | $180.50M 10-Q · filed 2025-11-04 | $413.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $34.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $106.31M 10-Q · filed 2026-08-04 | $339.40M derived: sum of 3 quarters · filed 2026-08-04 | $374.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $71.44M 10-Q · filed 2026-05-05 | $304.54M derived: sum of 2 quarters · filed 2026-05-05 | $339.59M derived: sum of 3 quarters · filed 2026-05-05 | $517.98M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $233.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $268.14M derived: sum of 2 quarters · filed 2026-02-19 | $446.54M derived: sum of 3 quarters · filed 2026-02-19 | $599.25M 10-K · filed 2026-02-19 |
| 2024-09-30 | $35.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $213.45M derived: sum of 2 quarters · filed 2025-11-04 | $366.16M 10-Q · filed 2025-11-04 | $420.33M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $178.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $331.11M 10-Q · filed 2025-08-05 | $385.28M derived: sum of 3 quarters · filed 2026-02-19 | $497.91M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $152.71M 10-Q · filed 2025-05-08 | $206.88M derived: sum of 2 quarters · filed 2026-02-19 | $319.52M derived: sum of 3 quarters · filed 2026-02-19 | $319.52M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $54.17M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $166.80M derived: sum of 2 quarters · filed 2026-02-19 | $166.80M derived: sum of 3 quarters · filed 2026-02-19 | $166.80M 10-K · filed 2026-02-19 |
| 2023-09-30 | $112.63M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $112.63M derived: sum of 2 quarters · filed 2024-11-18 | $112.63M 10-Q/A · filed 2024-11-18 | $117.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | $4.50M derived: sum of 3 quarters · filed 2025-02-27 | $11.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $0.00 10-Q/A · filed 2024-11-18 | $4.50M derived: sum of 2 quarters · filed 2025-02-27 | $11.75M derived: sum of 3 quarters · filed 2025-02-27 | $36.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $11.75M derived: sum of 2 quarters · filed 2025-02-27 | $36.00M derived: sum of 3 quarters · filed 2025-02-27 | $39.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | $7.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $31.50M derived: sum of 2 quarters · filed 2023-11-09 | $35.00M 10-Q · filed 2023-11-09 | $48.25M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | $24.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $27.75M 10-Q · filed 2023-08-11 | $41.00M derived: sum of 3 quarters · filed 2024-11-18 | $67.25M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | $3.50M 10-Q · filed 2023-05-11 | $16.75M derived: sum of 2 quarters · filed 2024-11-18 | $43.00M derived: sum of 3 quarters · filed 2024-11-18 | $112.33M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | $13.25M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $39.50M derived: sum of 2 quarters · filed 2024-11-18 | $108.83M derived: sum of 3 quarters · filed 2024-11-18 | $133.08M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $26.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $95.58M derived: sum of 2 quarters · filed 2022-11-03 | $119.83M 10-Q · filed 2022-11-03 | $150.83M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $69.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $93.58M 10-Q · filed 2022-08-04 | $124.58M derived: sum of 3 quarters · filed 2023-03-02 | $147.08M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $24.25M 10-Q · filed 2022-05-05 | $55.25M derived: sum of 2 quarters · filed 2023-03-02 | $77.75M derived: sum of 3 quarters · filed 2023-03-02 | $149.25M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $53.50M derived: sum of 2 quarters · filed 2023-03-02 | $125.00M derived: sum of 3 quarters · filed 2023-03-02 | $129.00M 10-K · filed 2023-03-02 |
| 2020-09-30 | $22.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $94.00M derived: sum of 2 quarters · filed 2021-11-04 | $98.00M 10-Q · filed 2021-11-04 | $102.25M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $71.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $75.50M 10-Q · filed 2021-08-05 | $79.75M derived: sum of 3 quarters · filed 2022-03-08 | $89.47M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $4.00M 10-Q · filed 2021-05-10 | $8.25M derived: sum of 2 quarters · filed 2022-03-08 | $17.97M derived: sum of 3 quarters · filed 2022-03-08 | $76.18M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $13.97M derived: sum of 2 quarters · filed 2022-03-08 | $72.18M derived: sum of 3 quarters · filed 2022-03-08 | $91.93M 10-K · filed 2022-03-08 |
| 2019-09-30 | $9.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $67.93M derived: sum of 2 quarters · filed 2020-11-05 | $87.68M 10-Q · filed 2020-11-05 | $114.36M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $58.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $77.96M 10-Q · filed 2020-08-10 | $104.64M derived: sum of 3 quarters · filed 2021-03-18 | $113.89M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $19.75M 10-Q · filed 2020-05-07 | $46.43M derived: sum of 2 quarters · filed 2021-03-18 | $55.68M derived: sum of 3 quarters · filed 2021-03-18 | |
| 2018-12-31 | $26.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $35.93M derived: sum of 2 quarters · filed 2021-03-18 | $62.18M 10-K · filed 2021-03-18 | |
| 2018-09-30 | $9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $35.50M 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $26.25M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $64.11M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |